ArticleNeurology. Genetics2026
Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Cerebral small vessel disease (cSVD) is a common cause of stroke and dementia without available definitive treatments. Glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized the management of diabetes and obesity and have shown benefits in reducing cardiovascular risk, but it remains unknown if they could lower the burden of cSVD manifestations. Here, we investigated associations between genetic variants that mimic the action of GLP-1R agonists and cSVD phenotypes. Methods: We applied a drug target Mendelian Randomization (MR) analysis using single-nucleotide polymorphisms (SNPs) within and near the Results: Our Discussion: Our study found that genetically proxied GLP-1 receptor agonism is associated with lower burden of clinical and imaging cSVD outcomes. These findings provide a rationale for clinical trials evaluating GLP-1 receptor agonists as a potential strategy to prevent cSVD progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.